Holen Sie sich die Stockscreener-App
38.49
1.42%
0.54
Handel nachbörslich:
38.78
0.29
+0.75%
Schlusskurs vom Vortag:
$37.95
Offen:
$38.04
24-Stunden-Volumen:
2.54M
Relative Volume:
0.69
Marktkapitalisierung:
$10.36B
Einnahmen:
$2.17B
Nettoeinkommen (Verlust:
$521.27M
KGV:
21.75
EPS:
1.77
Netto-Cashflow:
$633.79M
1W Leistung:
+2.07%
1M Leistung:
-14.20%
6M Leistung:
+11.60%
1J Leistung:
+44.16%
1-Tages-Spanne:
$37.83
$38.78
1-Wochen-Bereich:
$37.01
$38.78
52-Wochen-Spanne:
$25.12
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Vergleichen Sie EXEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
38.49 | 10.07B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Lost Money on Exelixis, Inc. (EXEL)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - Bluefield Daily Telegraph
Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth? - Yahoo Finance
What Fibonacci levels say about Exelixis Inc. reboundWeekly Stock Movement Prediction Watchlist - Newser
Exelixis stock price target lowered to $46 at H.C. Wainwright on SCCHN trial halt - Investing.com Nigeria
Levi & Korsinsky Investigating Whether Exelixis, Inc. (EXEL) Misled InvestorsSecurities Law Violations Possible - ACCESS Newswire
LPL Financial LLC Increases Position in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
ATTENTION EXEL Shareholders: Lost Money on Exelixis, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Ongoing Securities Investigation into Exelixis, Inc. (EXEL)Contact Levi & Korsinsky - ACCESS Newswire
Exelixis’ CABOMETYX Receives EU Approval for Neuroendocrine Tumor Treatment - Insider Monkey
Is Exelixis Inc. stock bottoming outPre-Market Stock Movement Summary and Review - Newser
Exelixis reports Q2 net product revenues 2% below consensus estimate. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXEL - GlobeNewswire Inc.
Identifying reversal signals in Exelixis Inc.Trend Confirmation Scanner with Entry Focus - Newser
Relative strength of Exelixis Inc. in sector analysisProfit Target Planning with Exit Confidence - Newser
Can Exelixis Inc. be recession proofTriple Digit Stock Opportunities - sisaissue.com
Live market analysis of Exelixis Inc.Free Daily Growth Stock Pick Reports - Newser
Exelixis, Inc. (NASDAQ:EXEL) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - 富途牛牛
Lost Money on Exelixis, Inc. (EXEL)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Levi & Korsinsky Investigates Exelixis, Inc. (EXEL) Over Possible Securities Fraud - ACCESS Newswire
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Mutual of America Capital Management LLC - Defense World
Momentum Screeners Rank Exelixis Inc. in Top 5 TodaySafe Entry Stock Watch Suggestions for Cautious Traders - beatles.ru
Will Exelixis Inc. continue its uptrendDaily Technical Forecast for Quick Gains - Newser
Is it too late to sell Exelixis Inc.Strategy Builder for Growth Focused Traders - Newser
How to use a screener to detect Exelixis Inc. breakoutsRisk Shielded Trade Watch with Analysis - Newser
Investors in Exelixis, Inc. (EXEL) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Exelixis, Inc. (EXEL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Signal strength of Exelixis Inc. stock in tech scannersRSI Divergence and Support Breakout Analysis - Newser
Levi & Korsinsky Investigates Possible Securities Fraud by Exelixis, Inc. (EXEL) - ACCESS Newswire
Potential Securities Fraud: Levi & Korsinsky Investigates Exelixis, Inc. (EXEL) - ACCESS Newswire
Exelixis, Inc. (EXEL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Exelixis Q2 net product revenues miss consensus by 2%, down 2%. - AInvest
Can Exelixis Inc. recover in the next quarterBuy and Hold Strategy for Capital Safety - Newser
Why Exelixis Inc. stock attracts strong analyst attentionFree Optimized Watchlist With Daily Adjustments - Newser
Avantax Advisory Services Inc. Makes New $551,000 Investment in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Will Exelixis Inc. see short term momentumFundamental Forecast for Undervalued Stocks - Newser
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Exelixis, Inc. (EXEL) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Securities Investigation: Levi & Korsinsky Investigates Exelixis, Inc. (EXEL) on Behalf of Investors - ACCESS Newswire
Exelixis, Inc. : The cure to cancer? - MarketScreener
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock? - TradingView
Exelixis (NASDAQ:EXEL) Cut to “Buy” at Wall Street Zen - Defense World
Exelixis EXEL Q2 2025 Earnings Call Transcript - AOL.com
Bronstein, Gewirtz & Grossman, LLC Encourages Exelixis, Inc. (EXEL) Investors to Inquire about Securities Investigation - ACCESS Newswire
Live market analysis of Exelixis IncReal Time Growth Signal with Smart Setup - Newser
Don't Overlook Exelixis (EXEL) International Revenue Trends While Assessing the Stock - Yahoo Finance
Exelixis Inc. Chart Enters High Volatility ZoneTriple Digit Return Stock Predictions Released - beatles.ru
Exelixis (EXEL) Tumbles 16.8% as Q2 Earnings Disappoint - MSN
How strong is Exelixis Inc. company’s balance sheetBoost your returns with professional guidance - Jammu Links News
What makes Exelixis Inc. stock price move sharplyMassive wealth growth - Jammu Links News
What are analysts’ price targets for Exelixis Inc. in the next 12 monthsSky-high return potential - Jammu Links News
Is Exelixis Inc. a good long term investmentOutstanding trading profits - Jammu Links News
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):